Anxiety and FearPhase 2NCT04526652
Evaluating Stress Response and Anxiety Score in Paediatric Patients
A Phase 2 study testing Dexmedetomidine in people with Anxiety and Fear and Anesthesia, run by Universiti Sains Malaysia at 1 site in Malaysia.
Trial summary
To date, there have been no studies done relating serum cortisol levels and intranasal dexmedetomidine sedation. However, there was a behavioral study done on pediatric patients confirming reduction serum cortisol levels with perioperative dialogue intervention.There have been a number of studies done on adult… Read more about this study
- Who is it for?
- Ages 1 year to 12 yearsHealthy volunteers can take part
- Conditions the study is for
- Anxiety and Fear, Anesthesia
- What is being tested?
- Dexmedetomidine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 60 participants
- Where
- 1 siteMalaysia
- Study dates
- 1 Dec 2020to 1 Aug 2021
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 year to 12 years
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- Pediatric patients age 1-12 years old
- Weight of patient between 10 - 60 kgs
- American Society of Anesthesiologist (ASA) I or II
- Scheduled for elective and emergency surgeries
- Caregivers able to understand and provide informed consent
Who cannot join
- Allergy to study drugs (dexmedetomidine, morphine, paracetamol etc.)
- Special need Children (Cerebral palsy, down syndrome, ADHD, ASD)
- Serious cardiac/respiratory diseases.
- Children with neuromuscular disorders or neurological diseases (epilepsy etc)
- Children with Metabolic disorders
- Difficult airway cases
- Children on any kind of steroid therapy / HPA diseases
Trial locations and contacts
1 site in 1 country.
Malaysia1 site
Hospital Universiti Sains Malaysia
Kota Bharu, Kelantan, 15200
About this study
Official title: Evaluating Stress Response and Anxiety Score in Paediatric Patients Sedated With Intranasal Dexmedetomidine
To date, there have been no studies done relating serum cortisol levels and intranasal dexmedetomidine sedation. However, there was a behavioral study done on pediatric patients confirming reduction serum cortisol levels with perioperative dialogue intervention.There have been a number of studies done on adult patients indicating that dexmedetomidine was indeed capable of reducing level of anxiety with evidence of lower serum cortisol levels. Hence, we postulated that intranasal dexmedetomidine administration in pediatric patients will lower the serum cortisol levels but we need to evaluate the extent of reduction.
Read the detailed description
Justification of study
With increase in number of pediatric patients undergoing surgery, efforts need to be placed on improving quality of perioperative care and patient comfort Intranasal administration of sedative agents will be far more comfortable and create a better environment for patients as most children have a fear of needles and may resist intravenous drug administration Intranasal administration is also a far simpler and less time-consuming technique with good bioavailability of administered drugs Reduction in postoperative analgesia requirement will result in early return to daily life activities, early discharge and overall reduced length of stay and hospital costs
Pre and intraoperative
All perioperative data will be collected by an investigator who is blinded to the patient's allocation. Once the caregiver has agreed and consented to participate in this study, upon admission (1 day prior to scheduled surgery) a baseline serum cortisol level will be taken concurrent with IV line setting and blood investigations. The fasting time for all patients will be at least 6 hours prior to surgery with clear fluids being allowed up to 2 hours prior to surgery.
On the day of surgery, the patient and caregiver will be called upon 1 hour prior to operating time and baseline hemodynamic parameters will be recorded (blood pressure, heart rate and pulse oximetry SpO2). Baseline Modified Yale Preoperative Anxiety Scale (m-YPAS) will be used as an assessment tool for measuring level of preoperative anxiety.
Baseline Modified Yale Preoperative Anxiety scale (m-YPAS) is an established and recognized tool for assessment of pediatric anxiety levels preoperatively. It is an observational checklist each consisting of four to six distinct behavioral descriptions. Four categories of behavior are assessed: activity, vocalizations, emotional expressivity, and state of apparent arousal. Partial weights are used to calculate a total score ranging from 23 (low anxiety) to 100 (high anxiety). Previous research has shown good to excellent inter and intra-observer reliability and validity.
Once the baseline parameters have been recorded, patient will receive the medication previously assigned via randomization delivered via mucosal atomizer device (MAD). Drugs will be administered by anesthetist or anesthetic medical officer only in safe setting with drugs for resuscitation and monitoring equipment available. They will be briefed on the workflow and timing of drug administration accordingly. The person responsible for delivering the medication will be blinded.
Hemodynamic parameters will be charted at 10 minutes intervals after the study medications have been served. Rescue drugs IV atropine 10 - 20mcg/kg will be given if the patient develops bradycardia (less than 2SDs for age) and fluid boluses if blood pressure drops to more than 20% of baseline or below 2SD of blood pressure for age.
2nd Modified Yale Preoperative Anxiety Scale (m-YPAS) will be assessed 10 minutes after delivering the study medications. This is followed by sedation score after 30 minutes and 3rd. m-YPAS if indicated.
Sedation and behavior score is a simplified scoring system that is based on observational charting. It comprises of 2 domains ranging from alert, awake, crying and resisting to asleep and not responding to mild prodding or shaking while being calm and cooperative. Higher scores indicate a higher level of sedation and are more favorable.
Once the patient has arrived in the operation theatre, the SpO2 monitoring probe will be attached and intravenous induction is carried out with IV Propofol 4 - 5mg/kg. This is followed by applying other standard monitoring appliances such as blood pressure cuff and ECG electrodes. IV fentanyl 1-2mcg/kg to obtund the laryngeal reflex and paralysis with IV esmeron 0.6-1mg/kg. Appropriate size endotracheal tubes (ETT) or laryngeal mask airway (LMA) will be inserted accordingly to secure the airway.
2nd sample of serum cortisol level will be taken within 10 minutes of induction of anesthesia. Maintenance of anesthesia with sevoflurane aiming at 1.0 minimum alveolar concentration (MAC). Intravenous fluid will be replaced according to (Holiday Segar Formula) using either HM solution or sterofundin.
IV paracetamol 15mg/kg will be given pre-emptively, followed by IV morphine 0.1mg/kg. IV Fentanyl boluses 0.5-1mcg/kg will be served if required based on the hemodynamic parameters.
Postoperative
Postoperatively patient will be monitored in recovery room for 30 minutes and pain will be assessed using Wong Baker Faces pain rating scale/FLACC for smaller children. Rescue analgesic IV Fentanyl 0.5-1mcg/kg will be given if required. The total requirement of IV Fentanyl and the discharge time will be recorded for reference.
Wong Baker Faces scale is tool created with children to help them communicate their pain. Now the scale is used around the world with people ages 3 and older, facilitating communication and improving assessment so pain management can be addressed accordingly. There are 6 faces with each face representing a person who has no pain (hurt), or some, or a lot of pain. The patient chooses the face that best depicts the pain they are experiencing.
The FLACC scale or Face, Legs, Activity, Cry, Consolability scale is a measurement used to assess pain for children between the ages of 2 months and 7 years or individuals that are unable to communicate their pain. It is an observational based scale. The scale is scored in a range of 0-10 with 0 representing no pain. The scale has five criteria, which are each assigned a score of 0, 1 or 2. Higher scores indicate higher pain.
Statistical Analysis
The analyses will be performed using the IBM SPSS Statistics for Windows Version 21.0. The data will be manually entered into the software before the cleaning process takes place. The cleaning process is crucial to prevent any errors that may skew the results. After that, the actual analysis process will be carried out. In this study, descriptive statistics will be employed for selected variables. The findings will be presented based on the types of data and their distribution. Categorical Data, will be presented as frequencies and percentage. Numerical Data will be presented as means and standard deviations if normally distributed, and if not, as medians and interquartile ranges.
Comparison of Numerical Data between two independent groups that are normally distributed will be analyzed using the Independent t-test, while Mann-Whitney test will be used if the data for two independent groups are not normally distributed.
Hemodynamic parameters measurement (objective 3) will be analyzed using repeated measures ANOVA while Friedman test will be used if the Numerical Data are not normally distributed. All probability values are two-sided, and a level of significance of less than 0.05 (p-value < 0.05) will be considered as statistically significant
- Conditions
- Anxiety and Fear, Anesthesia
- Being tested
- Dexmedetomidine, Placebo
- Keywords
- Paediatric, Intranasal, General anaesthesia, Dexmedetomidine, Anxiety score, cortisol
- Medical subject headings
- Anxiety Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DexmedetomidineDrug
Evaluating anxiety score in both arms
PlaceboDrug
Evaluating anxiety score in both arms
| Study group | Role | What they receive |
|---|---|---|
| Dexmedetomidine | Active comparator | Intranasal dexmedetomidine 1mcg/kg Receives: Drug: Dexmedetomidine |
| Placebo | Placebo comparator | Intranasal normal saline equivalent to (1mcg/kg dose of dexmedetomidine) Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Evaluating stress response
Evaluating stress response by measuring serum cortisol level (nmol/L)
Measured: Baseline: (before giving study drugs) and 1 to half an hour after drugs given
Evaluating anxiety score
To compare mean anxiety score using modified Yale Preoperative Anxiety Scales (m-YPAS)
Measured: Baseline:(before giving study drugs) and 1 to half an hour after drugs given
Secondary outcomes (3)
Safety profile of Intranasal Dexmedetomidine in paediatric patients
Monitoring the haemodynamic parameters (blood pressure in mmHg)
Measured: Baseline and 10 minutes interval after study drugs given
Safety profile of Intranasal Dexmedetomidine in paediatric patients
Monitoring the haemodynamic parameters (heart rate in beats per minute)
Measured: Baseline and 10 minutes interval after study drugs given
Safety profile of Intranasal Dexmedetomidine in paediatric patients
Monitoring the haemodynamic parameters (Oxygen saturation in percentage)
Measured: Baseline and 10 minutes interval after study drugs given
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Aug 2020
- Study start1 Dec 2020
- Primary completion31 Jul 2021
- Study completion1 Aug 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Anxiety and FearStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Randomization of paediatric patients for general anaesthesia one arm: Intranasal dexmedetomidine another arm: Intranasal normal saline (placebo)
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- Universiti Sains Malaysia
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Huda Zainal Abidin, Universiti Sains Malaysia
- Investigators
- Huda Zainal Abidin, MD, Principal investigator, Universiti Sains Malaysia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04526652
- Sponsor's protocol ID
- A82010307
- Status last verified
- Oct 2021
- First submitted
- 4 Aug 2020
- Last updated
- 25 Oct 2021
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: IPD will be considered for sharing if the the data is to be used for related study
Publications
Isik B, Arslan M, Tunga AD, Kurtipek O. Dexmedetomidine decreases emergence agitation in pediatric patients after sevoflurane anesthesia without surgery. Paediatr Anaesth. 2006 Jul;16(7):748-53. doi: 10.1111/j.1460-9592.2006.01845.x.
PubMed 16879517Hall JE, Uhrich TD, Barney JA, Arain SR, Ebert TJ. Sedative, amnestic, and analgesic properties of small-dose dexmedetomidine infusions. Anesth Analg. 2000 Mar;90(3):699-705. doi: 10.1097/00000539-200003000-00035.
PubMed 10702460Yuen VM, Hui TW, Irwin MG, Yao TJ, Chan L, Wong GL, Shahnaz Hasan M, Shariffuddin II. A randomised comparison of two intranasal dexmedetomidine doses for premedication in children. Anaesthesia. 2012 Nov;67(11):1210-6. doi: 10.1111/j.1365-2044.2012.07309.x. Epub 2012 Sep 5.
PubMed 22950484Yuen VM, Hui TW, Irwin MG, Yao TJ, Wong GL, Yuen MK. Optimal timing for the administration of intranasal dexmedetomidine for premedication in children. Anaesthesia. 2010 Sep;65(9):922-9. doi: 10.1111/j.1365-2044.2010.06453.x.
PubMed 20645951Akin A, Bayram A, Esmaoglu A, Tosun Z, Aksu R, Altuntas R, Boyaci A. Dexmedetomidine vs midazolam for premedication of pediatric patients undergoing anesthesia. Paediatr Anaesth. 2012 Sep;22(9):871-6. doi: 10.1111/j.1460-9592.2012.03802.x. Epub 2012 Jan 23.
PubMed 22268591
Study at a glance
From the registry record, last updated by the sponsor on 25 Oct 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluating Stress Response and Anxiety Score in Paediatric Patients Sedated With Intranasal Dexmedetomidine
- ClinicalTrials.gov ID
- NCT04526652
- Acronym / sponsor ID
- A82010307
- Conditions
- Anxiety and Fear, Anesthesia
- Keywords
- Paediatric, Intranasal, General anaesthesia, Dexmedetomidine, Anxiety score, cortisol
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- Universiti Sains MalaysiaUniversity, hospital or other
- Study start
- 1 Dec 2020 (actual)
- Primary completion
- 31 Jul 2021 (actual)
- Study completion
- 1 Aug 2021 (actual)
- First posted
- 26 Aug 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To date, there have been no studies done relating serum cortisol levels and intranasal dexmedetomidine sedation. However, there was a behavioral study done on pediatric patients confirming reduction serum cortisol levels with perioperative dialogue intervention.There have been a number of studies done on adult patients indicating that dexmedetomidine was indeed capable of reducing level of anxiety with evidence of lower serum cortisol levels. Hence, we postulated that intranasal dexmedetomidine administration in pediatric patients will lower the serum cortisol levels but we need to evaluate the extent of reduction.
Detailed description
Justification of study
With increase in number of pediatric patients undergoing surgery, efforts need to be placed on improving quality of perioperative care and patient comfort Intranasal administration of sedative agents will be far more comfortable and create a better environment for patients as most children have a fear of needles and may resist intravenous drug administration Intranasal administration is also a far simpler and less time-consuming technique with good bioavailability of administered drugs Reduction in postoperative analgesia requirement will result in early return to daily life activities, early discharge and overall reduced length of stay and hospital costs
Pre and intraoperative
All perioperative data will be collected by an investigator who is blinded to the patient's allocation. Once the caregiver has agreed and consented to participate in this study, upon admission (1 day prior to scheduled surgery) a baseline serum cortisol level will be taken concurrent with IV line setting and blood investigations. The fasting time for all patients will be at least 6 hours prior to surgery with clear fluids being allowed up to 2 hours prior to surgery.
On the day of surgery, the patient and caregiver will be called upon 1 hour prior to operating time and baseline hemodynamic parameters will be recorded (blood pressure, heart rate and pulse oximetry SpO2). Baseline Modified Yale Preoperative Anxiety Scale (m-YPAS) will be used as an assessment tool for measuring level of preoperative anxiety.
Baseline Modified Yale Preoperative Anxiety scale (m-YPAS) is an established and recognized tool for assessment of pediatric anxiety levels preoperatively. It is an observational checklist each consisting of four to six distinct behavioral descriptions. Four categories of behavior are assessed: activity, vocalizations, emotional expressivity, and state of apparent arousal. Partial weights are used to calculate a total score ranging from 23 (low anxiety) to 100 (high anxiety). Previous research has shown good to excellent inter and intra-observer reliability and validity.
Once the baseline parameters have been recorded, patient will receive the medication previously assigned via randomization delivered via mucosal atomizer device (MAD). Drugs will be administered by anesthetist or anesthetic medical officer only in safe setting with drugs for resuscitation and monitoring equipment available. They will be briefed on the workflow and timing of drug administration accordingly. The person responsible for delivering the medication will be blinded.
Hemodynamic parameters will be charted at 10 minutes intervals after the study medications have been served. Rescue drugs IV atropine 10 - 20mcg/kg will be given if the patient develops bradycardia (less than 2SDs for age) and fluid boluses if blood pressure drops to more than 20% of baseline or below 2SD of blood pressure for age.
2nd Modified Yale Preoperative Anxiety Scale (m-YPAS) will be assessed 10 minutes after delivering the study medications. This is followed by sedation score after 30 minutes and 3rd. m-YPAS if indicated.
Sedation and behavior score is a simplified scoring system that is based on observational charting. It comprises of 2 domains ranging from alert, awake, crying and resisting to asleep and not responding to mild prodding or shaking while being calm and cooperative. Higher scores indicate a higher level of sedation and are more favorable.
Once the patient has arrived in the operation theatre, the SpO2 monitoring probe will be attached and intravenous induction is carried out with IV Propofol 4 - 5mg/kg. This is followed by applying other standard monitoring appliances such as blood pressure cuff and ECG electrodes. IV fentanyl 1-2mcg/kg to obtund the laryngeal reflex and paralysis with IV esmeron 0.6-1mg/kg. Appropriate size endotracheal tubes (ETT) or laryngeal mask airway (LMA) will be inserted accordingly to secure the airway.
2nd sample of serum cortisol level will be taken within 10 minutes of induction of anesthesia. Maintenance of anesthesia with sevoflurane aiming at 1.0 minimum alveolar concentration (MAC). Intravenous fluid will be replaced according to (Holiday Segar Formula) using either HM solution or sterofundin.
IV paracetamol 15mg/kg will be given pre-emptively, followed by IV morphine 0.1mg/kg. IV Fentanyl boluses 0.5-1mcg/kg will be served if required based on the hemodynamic parameters.
Postoperative
Postoperatively patient will be monitored in recovery room for 30 minutes and pain will be assessed using Wong Baker Faces pain rating scale/FLACC for smaller children. Rescue analgesic IV Fentanyl 0.5-1mcg/kg will be given if required. The total requirement of IV Fentanyl and the discharge time will be recorded for reference.
Wong Baker Faces scale is tool created with children to help them communicate their pain. Now the scale is used around the world with people ages 3 and older, facilitating communication and improving assessment so pain management can be addressed accordingly. There are 6 faces with each face representing a person who has no pain (hurt), or some, or a lot of pain. The patient chooses the face that best depicts the pain they are experiencing.
The FLACC scale or Face, Legs, Activity, Cry, Consolability scale is a measurement used to assess pain for children between the ages of 2 months and 7 years or individuals that are unable to communicate their pain. It is an observational based scale. The scale is scored in a range of 0-10 with 0 representing no pain. The scale has five criteria, which are each assigned a score of 0, 1 or 2. Higher scores indicate higher pain.
Statistical Analysis
The analyses will be performed using the IBM SPSS Statistics for Windows Version 21.0. The data will be manually entered into the software before the cleaning process takes place. The cleaning process is crucial to prevent any errors that may skew the results. After that, the actual analysis process will be carried out. In this study, descriptive statistics will be employed for selected variables. The findings will be presented based on the types of data and their distribution. Categorical Data, will be presented as frequencies and percentage. Numerical Data will be presented as means and standard deviations if normally distributed, and if not, as medians and interquartile ranges.
Comparison of Numerical Data between two independent groups that are normally distributed will be analyzed using the Independent t-test, while Mann-Whitney test will be used if the data for two independent groups are not normally distributed.
Hemodynamic parameters measurement (objective 3) will be analyzed using repeated measures ANOVA while Friedman test will be used if the Numerical Data are not normally distributed. All probability values are two-sided, and a level of significance of less than 0.05 (p-value < 0.05) will be considered as statistically significant
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Randomization of paediatric patients for general anaesthesia one arm: Intranasal dexmedetomidine another arm: Intranasal normal saline (placebo)
| Arm | Type | Receives |
|---|---|---|
| Dexmedetomidine | Active comparator | Drug: DexmedetomidineIntranasal dexmedetomidine 1mcg/kg |
| Placebo | Placebo comparator | Drug: PlaceboIntranasal normal saline equivalent to (1mcg/kg dose of dexmedetomidine) |
Who may qualify
- Ages
- 1 year to 12 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Key inclusion criteria (5 listed)
- Pediatric patients age 1-12 years old
- Weight of patient between 10 - 60 kgs
- American Society of Anesthesiologist (ASA) I or II
- Scheduled for elective and emergency surgeries
- Caregivers able to understand and provide informed consent
Key exclusion criteria (7 listed)
- Allergy to study drugs (dexmedetomidine, morphine, paracetamol etc.)
- Special need Children (Cerebral palsy, down syndrome, ADHD, ASD)
- Serious cardiac/respiratory diseases.
- Children with neuromuscular disorders or neurological diseases (epilepsy etc)
- Children with Metabolic disorders
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| DexmedetomidineEvaluating anxiety score in both arms | Drug | Dexmedetomidine |
| PlaceboEvaluating anxiety score in both arms | Drug | Placebo |
Primary outcome
Evaluating stress response
Time frame: Baseline: (before giving study drugs) and 1 to half an hour after drugs given
Evaluating stress response by measuring serum cortisol level (nmol/L)
Evaluating anxiety score
Time frame: Baseline:(before giving study drugs) and 1 to half an hour after drugs given
To compare mean anxiety score using modified Yale Preoperative Anxiety Scales (m-YPAS)
3 secondary outcomes
Safety profile of Intranasal Dexmedetomidine in paediatric patients
Time frame: Baseline and 10 minutes interval after study drugs given
Safety profile of Intranasal Dexmedetomidine in paediatric patients
Time frame: Baseline and 10 minutes interval after study drugs given
Safety profile of Intranasal Dexmedetomidine in paediatric patients
Time frame: Baseline and 10 minutes interval after study drugs given
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Oct 2021.
- Background: PubMed 16879517Isik B, Arslan M, Tunga AD, Kurtipek O. Dexmedetomidine decreases emergence agitation in pediatric patients after sevoflurane anesthesia without surgery. Paediatr Anaesth. 2006 Jul;16(7):748-53. doi: 10.1111/j.1460-9592.2006.01845.x.
- Background: PubMed 10702460Hall JE, Uhrich TD, Barney JA, Arain SR, Ebert TJ. Sedative, amnestic, and analgesic properties of small-dose dexmedetomidine infusions. Anesth Analg. 2000 Mar;90(3):699-705. doi: 10.1097/00000539-200003000-00035.
- Background: PubMed 22950484Yuen VM, Hui TW, Irwin MG, Yao TJ, Chan L, Wong GL, Shahnaz Hasan M, Shariffuddin II. A randomised comparison of two intranasal dexmedetomidine doses for premedication in children. Anaesthesia. 2012 Nov;67(11):1210-6. doi: 10.1111/j.1365-2044.2012.07309.x. Epub 2012 Sep 5.
- Background: PubMed 20645951Yuen VM, Hui TW, Irwin MG, Yao TJ, Wong GL, Yuen MK. Optimal timing for the administration of intranasal dexmedetomidine for premedication in children. Anaesthesia. 2010 Sep;65(9):922-9. doi: 10.1111/j.1365-2044.2010.06453.x.
- Background: PubMed 22268591Akin A, Bayram A, Esmaoglu A, Tosun Z, Aksu R, Altuntas R, Boyaci A. Dexmedetomidine vs midazolam for premedication of pediatric patients undergoing anesthesia. Paediatr Anaesth. 2012 Sep;22(9):871-6. doi: 10.1111/j.1460-9592.2012.03802.x. Epub 2012 Jan 23.
- Individual participant dataSharing planned: No. IPD will be considered for sharing if the the data is to be used for related study
Related trials for Anxiety and Fear
Recruiting
Effects of Virtual Reality Environments on Walking in Adults With and Without Knee Osteoarthritis
Knee Osteoarthritis
Not yet recruiting
Multicomponent Exercise and Pain Science Education for Fall Prevention in Older Adults With Chronic Musculoskeletal Pain (MovePainFall)
Chronic Pain, Musculoskeletal Pain
Not yet recruiting
Coloring Activity Applied During Labor in Primiparous Pregnant Women and Its Effect on Birth Anxiety and Fear of Childbirth
Fear of Childbirth, Mandala Coloring
Active, not recruitingObservational study
The Impact of Osteosarcopenia on Falls, Kinesiophobia, and Quality of Life in Postmenopausal Women
Osteosarcopenia, Sarcopenia
Not yet recruitingPhase 2
Psilocybin FCR Early-Stage Breast Cancer
Early-stage Breast Cancer, Fear of Cancer Recurrence
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Huda Zainal Abidin, MD principal investigator
Universiti Sains Malaysia
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Dexmedetomidine in people with Anxiety and Fear and Anesthesia, run by Universiti Sains Malaysia at 1 site in Malaysia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 25 Oct 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Malaysia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Evaluating stress response (time frame: Baseline: (before giving study drugs) and 1 to half an hour after drugs given). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04526652, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Oct 2021.